Literature DB >> 7793179

Plasma cholinesterase and abnormal reaction to succinylcholine: twenty years' experience with the Danish Cholinesterase Research Unit.

F S Jensen1, J Viby-Mogensen.   

Abstract

For more than 20 years, the Danish Cholinesterase Research Unit (DCRU) has collected information about patients showing an abnormal response to succinylcholine. The purpose of this study was, on the basis of the 20 years' experiences with the Unit, to evaluate our clinical findings in patients referred because of prolonged response following succinylcholine. Also, we wanted to evaluate the results of our prospective controlled studies of the effect of succinylcholine in patients with normal and abnormal plasma cholinesterase genotypes. An explanation for the apparent abnormal response to succinylcholine was found in 61.1% of the 1,247 patients referred to the Unit. Of the 1,247 patients, 28.5% were genotypically normal and 46.5% had an abnormal genotype. In the remaining 24.9% of the patients, the genotype could not be established. The time to sufficient recovery of neuromuscular function following succinylcholine 1.0-1.5 mg kg-1 was 15-30 min in patients heterozygous for one abnormal gene, 35-45 min in patients heterozygous for two abnormal genes and 90-180 min in patients homozygous for the atypical gene. Patients with two newly discovered genotypes (AK (5 patients) and AH (1 patient) showed slightly prolonged (20 min) and markedly prolonged (90 min) duration of action of succinylcholine, respectively. Our results indicate that it is a problem for many anaesthetists to correctly diagnose a prolonged response to succinylcholine. We therefore urge the anaesthetist always to use a peripheral nerve stimulator when faced with a case of apparent abnormal response to succinylcholine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793179     DOI: 10.1111/j.1399-6576.1995.tb04034.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

1.  Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population.

Authors:  Melih O Babaoglu; Turgay Ocal; Banu Bayar; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-01-21       Impact factor: 2.953

2.  Genetic mutations associated with susceptibility to perioperative complications in a longitudinal biorepository with integrated genomic and electronic health records.

Authors:  Nicholas J Douville; Sachin Kheterpal; Milo Engoren; Michael Mathis; George A Mashour; Whitney E Hornsby; Cristen J Willer; Christopher B Douville
Journal:  Br J Anaesth       Date:  2020-09-03       Impact factor: 9.166

Review 3.  Pharmacogenomic considerations for medications in the perioperative setting.

Authors:  Ellie H Jhun; Jeffrey L Apfelbaum; David M Dickerson; Sajid Shahul; Randall Knoebel; Keith Danahey; Mark J Ratain; Peter H O'Donnell
Journal:  Pharmacogenomics       Date:  2019-07       Impact factor: 2.638

4.  Is succinylcholine appropriate or obsolete in the intensive care unit?

Authors:  L H Booij
Journal:  Crit Care       Date:  2001-08-31       Impact factor: 9.097

5.  Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery.

Authors:  Hamdy Awad; Ahmed Ahmed; Richard D Urman; Nicoleta Stoicea; Sergio D Bergese
Journal:  Pharmgenomics Pers Med       Date:  2019-07-26

6.  Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex.

Authors:  Sorin J Brull; Mohamed Naguib
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.